News | December 02, 2023
Venus Remedies granted market authorizations in Saudi Arabia and Philippines
These regulatory approvals signify a significant milestone for Venus Remedies Limited
These regulatory approvals signify a significant milestone for Venus Remedies Limited
Norgestrel and Ethinyl Estradiol Tablets USP (RLD: Lo/Ovral-28) had estimated annual sales of US $33 million in the US
The product has been in-licensed from Strides and will be commercialized by Amneal
The product is expected to be launched in FY25
Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor
The receipt of this permission paves way for the launch of Olaparib film coated tablets in India
Acquisition underscores Merck’s ongoing commitment to developing treatments for neurodegenerative diseases
Dapagliflozin Tablets (RLD Farxiga) had estimated annual sales of USD 7282 million in the US
Pitavastatin Tablets are indicated as an adjunct to diet to reduce low-density lipoprotein cholesterol
Subscribe To Our Newsletter & Stay Updated
